Third Expedited Approval Pathway Coming To China In January
Executive Summary
China Food and Drug Administration is introducing a new priority-review designation pathway that many companies are expected to use, although it is not yet clear just how much time it will save compared with the standard approval process.
You may also be interested in...
China Ready For More Medtech Market Access Simplifications
Following the recent news of local trial exemptions for almost 160 types of medical devices and IVDs in China, the China Food and Drug Administration is preparing to introduce more market access regulatory simplifications for medtech companies entering the Chinese market.
Asia Reg Roundup: Updates From China, Taiwan And Korea
An end-of-year flurry of regulatory activity in the Asian medtech markets has kept industry on its toes, with initiatives in China, Taiwan and Korea, among other regions. But as Asia Regulatory Professional Association (ARPA) Secretary Jack Wong and ARQon consultant May Ng observe in this December update for Medtech Insight, governments and companies in certain markets might benefit from a little more pressure in view of the regulatory tasks they face.
China Seeks Feedback On Priority-Review Designation For Devices
The China Food and Drug Administration's proposed fast-track route would expedite reviews for medical devices addressing clinical priority areas.